There are 3161 resources available
691TiP - PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Presenter: Alison Schram
Session: Poster session 01
722P - Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
Presenter: Laurence Gladieff
Session: Poster session 01
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01